Scripps Research Logo

Daniel Hoyer, Ph.D.

Professor Adjunct
Department of Molecular Medicine
California Campus
Scripps VIVO Scientific Profile
dhoyer@scripps.edu
(858) 784-8402

Education

D.Sc. (Pharmacology), Louis Pasteur University 1981
Ph.D. (Pharmacology), Louis Pasteur University 1981

Professional Experience

2004-2017 Professor Adjunct, Chemical Physiology, The Scripps Research Institute
1983-2012 Director, Novartis leading scientist, Neuropsychiatry, Neuroscience research, Novartis
2003-2005 Director of Translational Biology, Neuropsychiatry, Novartis
2002-2005 Member Core Management Team, Neuroscience Research, NIBR Basel, Novartis
1981-1983 Postdoctoral Research Associate, Medical School, Pharmacology, University of Pennsylvania

Selected References

All Publications

Hoyer, D. 5-HT receptor nomenclature: Naming names, does it matter? A tribute to Maurice Rapport. (2017). ACS Chemical Neuroscience, 8(5), 908-919.

Palacios, J. M., Pazos, A. & Hoyer, D. A short history of the 5-HT2C receptor: From the choroid plexus to depression, obesity and addiction treatment. (2017). Psychopharmacology, 234(9-10), 1395-1418.

Jacobson, L. H., Hoyer, D., Fehlmann, D., Bettler, B., Kaupmann, K. & Cryan, J. F. Blunted 5-HT1A receptor-mediated responses and antidepressant-like behavior in mice lacking the GABA(B1a) but not GABA(B1b) subunit isoforms. (2017). Psychopharmacology, 234(9-10), 1511-1523.

Liddelow, S. & Hoyer, D. Astrocytes: adhesion molecules and immunomodulation. (2016). Current Drug Targets, 17(16), 1871-1881.

Andreetta, F., Carboni, L., Grafton, G., Jeggo, R., Whyment, A. D., van den Top, M., Hoyer, D., Spanswick, D. & Barnes, N. M. Hippocampal 5-HT7 receptors signal phosphorylation of the GluA1 subunit to facilitate AMPA receptor mediated-neurotransmission in vitro and in vivo. (2016). British Journal of Pharmacology, 173(9), 1438-1451. PMCID: PMC4831309.

Steckler, T., Curran, H. V., de Wit, H., Howes, O., Hoyer, D., Lucki, I., Miczek, K. A., Morrow, A. L., Price, L. H. & Robbins, T. W. Reporting guidelines for psychopharmacology. (2016). Psychopharmacology, 233(7), 1131-1134.

Feuerbach, D., Pezous, N., Weiss, M., Shakeri-Nejad, K., Lingenhoehl, K., Hoyer, D., Hurth, K., Bilbe, G., Pryce, C. R., McAllister, K., Chaperon, F., Kucher, K., et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. (2015). British Journal of Pharmacology, 172(5), 1292-1304. PMCID: PMC4337702.

Behnke, D., Cotesta, S., Hintermann, S., Fendt, M., Gee, C. E., Jacobson, L. H., Laue, G., Meyer, A., Wagner, T., Badiger, S., Chaudhari, V., Chebrolu, M., et al. Discovery of 1H-pyrazolo 3,4-b pyridines as potent dual orexin receptor antagonists (DORAs). (2015). Bioorganic & Medicinal Chemistry Letters, 25(23), 5555-5560.

Lewis, I., Schmid, H. A., Kneuer, R., Hoyer, D., Silva, A. P., Weckbecker, G., Bruns, C. & Pless, J. SOM230: a new therapeutic modality for Cushing's disease. (2014). Chimia, 68(7-8), 483-484.

Jacobson, L. H., Callander, G. E. & Hoyer, D. Suvorexant for the treatment of insomnia. (2014). Expert Review of Clinical Pharmacology, 7(6), 711-730.